Clin Osteol 2007; 12(4): 166-171

Alendronate: effectiveness in the range of metabolic diseasesShort communications

J. Rosa

Alendronate is the first aminobisphosphonate widely used for the treatment of postmenopausal osteoporosis. With respect to its me­ chanism of action based on bone turnover suppression mediated by inhibition of osteoclastic resorption, the effect of alendronate has also been analyzed in other forms of osteoporosis (glucocorticoid-induced osteoporosis, male osteoporosis), prevention of osteoporosis in postmenopausal women as well as in other less frequent metabolic bone diseases (Paget's disease, primary hyperparathyroidism, posttransplant conditions). The article focuses on its use in both current and potential indications, and concludes that alendronate is the best studied bisphosphonate.

Keywords: alendronate, osteoporosis, metabolic bone disease

Published: December 11, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa J. Alendronate: effectiveness in the range of metabolic diseases. Osteologický bulletin. 2007;12(4):166-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The alendronate once-weekly study group. Two-year results of once-weekly ad­ ministration of alendronate 70 mg for th sis. J Bone Miner Res 2002;17:1988-1996.
    2. van Beek ER, Cohen LH, Leroy IM et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33:805-811. Go to original source...
    3. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendron treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-3115. Go to original source...
    4. Liberman YA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mine­ ral density and the incid J Med 1995;333:1437-1443. Go to original source...
    5. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of ale nate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541. Go to original source...
    6. Cummings SR,, Black DM, Thompson TE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral from the fracture intervention trial. JAMA 1998;280:2077-2082. Go to original source...
    7. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, r domized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int I999;9:46I468.
    8. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendro­ nate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocri­ nol Metab 2000;85:4118 4124. Go to original source...
    9. Gonnelli S, Cepollaro C, Montagnani A, et al. Alendronate treatment in men primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003; 73:133-139. Go to original source...
    10. Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 2000;11:98-101. Go to original source...
    11. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteopo sis in men. N Engl J Med 2000;343:604-610. Go to original source...
    12. Ringe ID, Faber H, Dorst A Alendronate treatment of established primary osteo­ porosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5255. Go to original source...
    13. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly ale ronate in patients with osteoporosis: a randomized, double-blind, placebocontrolled study. Mayo Clin Proc 2002;77:1044-1052. Go to original source...
    14. Ringe JD, Orwoll E, Daifotis A, Lombardi A Treatment of mal cent advances with alendronate. Osteoporos Int 2002;13:195-199. Go to original source...
    15. Shimon I, Eshed V, Doolman R. Alendronate for osteoporos gen-repleted Hypogonadism. Osteoporos Int 2005;16:1591-1596. Go to original source...
    16. Miller PD, Schnitzer T, Emkey R, et al. teoporosis. ClinDrug Invest 2004;24:333-341. Go to original source...
    17. Hosking DH, Chilvers CED, Christiansen C, et al. Prevention of bone alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998938:485 492. Go to original source...
    18. Rossini M, Gatti S, Girardello S, et al. Effects of two intermittent alendronate gimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000;27:119-122. Go to original source...
    19. Saag KG, Emkey R, Schnitzer TS. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-299. Go to original source...
    20. Adachi JD, Saag KG, Delmas, PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A ran­ domized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:202-211. Go to original source...
    21. Emkey R, Delmas PD, Goemaere S, et al. Changes in bone mineral density follo­ wing discontinuation or continuation of alendronate therapy in glucocorticoid-tre­ ated patients. A retrospective, observational study. Arthritis Rheum 2003;48:1102-1108. Go to original source...
    22. Lau EMC, Woo J, Chan YH, Li M. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 2001;29:506-510. Go to original source...
    23. Cremers SCLM, van Hogezand R, Bänffer D, et al. Absorption of the oral bis­ phosphonate alendronate in osteoporotic patients with Crohn's disease. Osteopo­ ros Int 2005;16:1727-1730. Go to original source...
    24. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Jhget's di­ sease of bone: indications for treatment and review of current therapies. J Bone Miner Res 2007;21: 94-98. Go to original source...
    25. Siris ES, Weinstein RS, Altman R, et al. Comparative study of alendronate vs. etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996;81:961-967. Go to original source...
    26. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantati­ on. Osteoporos Int 2003;14:617-630. Go to original source...
    27. Braith RW, Magyari PM, Fulton MN, et al. Resistance exercise training and alend­ ronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. J Heart Lung Transplant 2003;22:1082-1090. Go to original source...
    28. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the pre­ vention of bone loss after cardiac transplantation. N Engl J Med 2004;350:767-776. Go to original source...
    29. Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001;16:2111-2117. Go to original source...
    30. Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 2002;34:2111-2113. Go to original source...
    31. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003;76: 1498-1502. Go to original source...
    32. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplan­ tation. J Bone Miner Res 2004;19:1919 -1932. Go to original source...
    33. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255. Go to original source...
    34. Bilezikian JP, Potts JT Jr, Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-5361. Go to original source...
    35. Brown EM. The pathophysiology of primary hyperparathyroidism. J Bone Miner Res 2002;17(Suppl 2):N24-N29.
    36. Adami S, Mian M, Bertoldo F, et al. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clin Endocrinol (Oxf) 1990;33:391-397. Go to original source...
    37. Strewler GJ. A 64-year-old woman with primary hyperparathyroidism. JAMA 2005;293:,1772-1779. Go to original source...
    38. Ihrker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocri­ nol Metab 2002;87: 44824489. Go to original source...
    39. Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly p with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001;16:113-119. Go to original source...
    40. Chow CC, Chan WB, Li JKY et al. Oral alendronate increases bone mineral den­ sity in postmenopausal women with primary hyperparathyroidism. J Clin Endoc­ rinol Metab 2003;88: 581-587. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.